Company news
Kodiak Sciences Inc (NASDAQ:KOD) news
Every Kodiak Sciences Inc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
August 13, 2026
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
August 10, 2026
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflamma...
August 6, 2026
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
May 28, 2026
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
May 7, 2026
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis P...
May 1, 2026
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
March 31, 2026
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority ...
March 26, 2026
Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
February 4, 2026
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purc...
December 18, 2025
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
December 16, 2025
Kodiak Sciences Announces Proposed Public Offering of Common Stock
December 15, 2025
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
November 13, 2025
Kodiak Sciences to Present at Upcoming Investor Conferences
November 12, 2025
Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving abs...
November 5, 2025
New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular ed...
September 15, 2025
Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflam...
September 2, 2025
Kodiak Sciences to Present at American Chemical Society Fall 2025
August 19, 2025
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results
August 13, 2025
Kodiak Sciences to Host Investor R&D Day on July 16, 2025
July 10, 2025
Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society
June 25, 2025
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
May 29, 2025
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
May 14, 2025
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases
May 1, 2025
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
March 27, 2025
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
March 10, 2025
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
February 4, 2025
Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 7, 2025
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results
November 14, 2024
Kodiak Sciences to Participate in Upcoming Investor Conferences
November 11, 2024
Kodiak Sciences to Present at Innovate Retina 2024
October 14, 2024
Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time
September 23, 2024
Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City
September 17, 2024
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results
August 14, 2024
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
May 29, 2024
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
May 15, 2024
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
May 13, 2024
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-...
May 2, 2024
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
March 28, 2024
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
March 26, 2024
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Deg...
January 30, 2024
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 4, 2024
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
November 14, 2023
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and f...
November 6, 2023
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH D...
November 1, 2023
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
October 11, 2023
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 8, 2023
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched eff...
September 7, 2023